Merck & Co. Inc. (MRK) Stock Price Prediction
AI-generated price target with bull & bear cases · Re-evaluated every trading morning and evening
Our AI model’s current price target for MRK is $138.63 — 8.7% above the latest price of $127.48.
Target vs 52-Week Range
Bull Case vs Bear Case
Bull Case
The bullish outlook for Merck is underpinned by several key factors. Recent FDA approvals, such as LIPFENDRA, the first once-daily oral PCSK9 inhibitor, and expanded indications for KEYTRUDA in bladder and endometrial cancers, are expected to drive significant revenue growth. Merck's robust and deep HIV pipeline, with forthcoming data at AIDS 2026, including once-weekly islatravir regimens and a new daily pill (IDVYNSO), presents substantial future commercial opportunities. Analysts have increased price targets for MRK, citing a strong pipeline and identifiable catalysts extending into 2026–2027. Strategic acquisitions and licensing deals have nearly tripled Merck's late-phase pipeline since 2021, with a potential commercial value exceeding $50 billion by the mid-2030s.
Bear Case
The primary concern for Merck is its substantial reliance on KEYTRUDA, which faces a loss of exclusivity in late 2028 or early 2029, presenting a significant 'patent cliff' risk to future revenues. The stock's current valuation, with P/E ratios considerably above both industry averages and historical medians, suggests that MRK may be overvalued, indicating a limited margin of safety for investors. Furthermore, a high dividend payout ratio of 95.77% raises concerns regarding the sustainability of future dividend payments. Recent reported losses in EPS and a year-over-year decline in net income and operating income also highlight potential weaknesses. Elevated debt levels compared to equity could pose risks, particularly in an economic downturn.
Model-assessed risk level: Medium
Key Catalysts to Watch
Further positive clinical trial results and regulatory approvals for pipeline drugs, especially from the HIV pipeline data at AIDS 2026.
Successful commercial launch and market adoption of newly approved drugs such as LIPFENDRA.
Updates on Merck's strategies to mitigate the impact of the upcoming KEYTRUDA patent cliff.
Next earnings report, scheduled for August 4, 2026.
Outcomes of ongoing strategic acquisitions and licensing agreements.
Technical Backdrop
RSI-14
58.9
50-Day MA
$120.79
200-Day MA
$99.21
From 52-Wk High
-1.6%
Full momentum breakdown: Is MRK overbought or oversold?
Model Notes
Merck & Co., Inc. (MRK) is a global pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of prescription medicines, vaccines, biologic therapies, and animal health products. Headquartered in Rahway, New Jersey, the company operates as MSD outside of the United States and Canada. Keytruda, an oncology drug, remains a significant revenue driver for Merck. Recent positive drug trial results and pipeline advancements, including FDA clearance for LIPFENDRA and expanded indications for KEYTRUDA, have contributed to investor optimism and upward stock movement.
MRK stock has demonstrated a steady uptrend since late June 2026, advancing from the mid-$110s to the low-$130s. The current price of $130.63 is trading above key moving averages, including the 20-day, 50-day, 100-day, and 200-day simple and exponential moving averages, signaling a firmly bullish trend. While the Relative Strength Index (RSI) indicates a 'Buy' or 'Neutral' stance, the hourly RSI at 70.11 suggests short-term overbought conditions, potentially leading to a brief pullback or consolidation. The stock is currently testing resistance levels around $124 and near-term resistance in the $127.98–$129.71 range.
Current Street Context
July 16, 2026The AI price target for Merck & Co. Inc. is $141.00. While specific consensus ratings were not immediately available, analysts expect Merck's earnings to grow significantly next year. Merck is expected to release its Q2 2026 earnings on August 4, 2026. Analysts are projecting an EPS of $0.23 for the upcoming report. The company's pipeline developments and the performance of its key drugs are crucial factors for its future outlook. Investors will be closely watching for updates on clinical trials and regulatory approvals. Price targets are estimates and not guaranteed outcomes.
Frequently Asked Questions
What is the price target for MRK?
How is this forecast generated?
How accurate are stock price predictions?
Will MRK stock go up?
How often does the AI target change?
Methodology
The price target, bull and bear cases, and risk level are produced by an AI model that reviews MRK’s fundamentals, technical posture, current news flow, and analyst commentary via live web search. It re-evaluates every trading morning and evening; the street-context commentary refreshes each trading evening.
Targets are estimates, not guarantees. No model reliably predicts short-term prices — treat this page as a structured summary of what current information might justify, alongside the risks that could break the thesis.
Not Financial Advice
This page is for education and information only. Indicators are mechanical calculations, AI commentary can contain errors, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a qualified financial advisor. See our full disclaimer.
Keep Digging on MRK
Merck & Co. Inc. Overview
Price, chart, analysis & financials
MRK: Overbought or Oversold?
Updated daily
MRK: Why Is It Moving?
Updated daily
MRK: Undervalued or Overvalued?
Updated daily
Same question, Healthcare peers